XML 13 R1.htm IDEA: XBRL DOCUMENT v3.25.4
Cover - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Feb. 20, 2025
Jun. 28, 2024
Document Information [Line Items]      
Document Type 10-K/A    
Document Annual Report true    
Document Period End Date Dec. 31, 2024    
Current Fiscal Year End Date --12-31    
Document Transition Report false    
Entity File Number 001-40046    
Entity Registrant Name Core Scientific, Inc./tx    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 86-1243837    
Entity Address, Address Line One 838 Walker Road    
Entity Address, Address Line Two Suite 21-2105    
Entity Address, City or Town Dover    
Entity Address, State or Province DE    
Entity Address, Postal Zip Code 19904    
City Area Code 512    
Local Phone Number 402-5233    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Entity Emerging Growth Company false    
Entity Small Business false    
ICFR Auditor Attestation Flag true    
Document Financial Statement Error Correction [Flag] true    
Document Financial Statement Restatement Recovery Analysis [Flag] true    
Entity Shell Company false    
Entity Public Float     $ 1,750
Entity Bankruptcy Proceedings, Reporting Current true    
Entity Common Stock, Shares Outstanding   294,122,589  
Documents Incorporated by Reference
Portions of the registrant’s proxy statement related to its 2025 Annual Stockholders’ Meeting to be filed subsequently are incorporated
by reference into this Part III of this Form 10-K.
    
Entity Central Index Key 0001839341    
Document Fiscal Year Focus 2024    
Document Fiscal Period Focus FY    
Amendment Flag true    
Amendment Description Core Scientific, Inc. (the “Company”) is amending its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as originally filed with the Securities and Exchange Commission (the "SEC") on February 27, 2025 (hereinafter referred to as the “Original Filing” and, as amended, the “Amendment”) and is separately amending its Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2025, June 30, 2025 and September 30, 2025 (such amended reports, together with this Amendment, the “Amended Reports”), in each case to correct identified errors in its previously issued consolidated financial statements as further described below as well as in Note 3 — Restatement of Previously Issued Financial Statements, in Item 8 of Part II, to the restated consolidated financial statements included in this Amendment.During the preparation of the consolidated financial statements for the year ended December 31, 2025, the Company determined that property, plant and equipment was overstated as a result of the improper continued capitalization of carrying values of assets committed to demolition in connection with the conversion of certain facilities from digital asset mining operations to high-performance computing colocation infrastructure, which impacted the Company's previously issued consolidated financial statements as of and for the year ended December 31, 2024, as well as the condensed consolidated financial statements as of and for the three and six months ended June 30, 2024, the three and nine months ended September 30, 2024, the three months ended March 31, 2025, the three and six months ended June 30, 2025, and the three and nine months ended September 30, 2025 (the “Non-Reliance Periods”). Specifically, the carrying values of assets committed to demolition were improperly capitalized rather than being written down to fair value through the recognition of impairment charges in the periods in which the commitment to demolish was made.The Company assessed the materiality of the errors, individually and in the aggregate, and concluded that the errors were material to the previously issued financial statements and such previously issued financial statements should no longer be relied upon. As a result, the Company is restating its previously issued consolidated financial statements for the “Non-Reliance Periods. As all material restatement information will be included in this Amendment and in the Amended Reports, the Company does not intend to amend any of the Company’s previously filed Quarterly Reports on Form 10-Q for the quarterly periods ended June 30, 2024 and September 30, 2024. Accordingly, investors and others should rely only on the financial information and other disclosures regarding the Non-Reliance Periods in the Amended Reports and in any future filings with the SEC (as applicable) and should not rely on any previously issued or filed reports, earnings releases and investor presentations and other communications describing the Company’s previously issued financial statements, financial results, and other related financial information related to the Non-Reliance Periods.The cumulative impact of the corrections on the consolidated balance sheet as of December 31, 2024 resulted in an overstatement of property, plant and equipment, net of approximately $122.9 million and a corresponding understatement of accumulated deficit of the same amount. The impact on the consolidated statements of operations for the year ended December 31, 2024 was an understatement of impairment of property, plant and equipment of approximately $122.9 million. The restatement had no impact on revenue, cost of revenue, or income tax expense, and no impact on net cash provided by or used in operating, investment, or finance activities for any period presented, as the corrections to net loss and impairment of property, plant and equipment are offsetting within cash flows from operating activities. There was no income tax effect as the Company maintains a full valuation allowance against its net deferred tax assets. As a result of the errors described above, the Company has identified a material weakness in its internal control over financial reporting, as described in more detail in Part II, Item 9A – Controls and Procedures. The Company’s management reevaluated the effectiveness of the Company’s internal control over financial reporting and disclosure controls and procedures and concluded that the Company’s internal control over financial reporting and disclosure controls and procedures were not effective as of the respective end dates of each of the Company’s fiscal years ended December 31, 2024 and December 31, 2025, and the Company’s disclosure controls and procedures were not effective as of the respective end dates of each of its interim Non-Reliance Periods within fiscal 2025. As a result of the material weakness, Marcum LLP, the Company’s independent registered public accounting firm for the fiscal year ended December 31, 2024, has reissued its report on internal control over financial reporting in this Amendment to an adverse opinion that internal control over financial reporting was ineffective as of December 31, 2024. A discussion of the Company’s plans to remediate this material weakness are set forth in Part II, Item 9A – “Controls and Procedures”.This Amendment amends and restates in their entirety the following items of the Original Filing:•Item 7 — Management’s Discussion and Analysis of Financial Condition and Results of Operations;• Item 8 — Financial Statements and Supplementary Data;•Item 9A — Controls and Procedures; and •Item 15 – Exhibits and Financial Statement Schedules.In addition, in accordance with Rule 12b-15 under the Securities Exchange Act of 1934, as amended, new certifications of the Company’s principal executive officer and principal financial officer are filed as exhibits to this Amendment, and the consent of the Company’s independent registered public accounting firm is re-filed.Except as described above, this Amendment does not amend, update or change any other items or disclosure contained in the Original Filing. This Amendment does not reflect events, results or developments occurring after the date of the Original Filing or modify or update the disclosures therein in any way, other than as required to reflect the effects of the restatement. Accordingly, forward-looking statements included in this Amendment represent management’s views as of the date of the Original Filing and should not be assumed to be accurate as of any date thereafter. This Amendment should be read in conjunction with the Original Filing and the Company’s filings with the SEC subsequent to the Original Filing.    
Common stock, par value $0.00001 per share      
Document Information [Line Items]      
Title of 12(b) Security Common stock, par value $0.00001 per share    
Trading Symbol CORZ    
Security Exchange Name NASDAQ    
Warrants, each whole warrant exercisable for one share of common stock at an exercise price of $6.81 per share      
Document Information [Line Items]      
Title of 12(b) Security Warrants, each whole warrant exercisable for one share of common stock at an exercise price of $6.81 per share    
Trading Symbol CORZW    
Security Exchange Name NASDAQ    
Warrants, each whole warrant exercisable for one share of common stock at an exercise price of $0.01 per share      
Document Information [Line Items]      
Title of 12(b) Security Warrants, each whole warrant exercisable for one share of common stock at an exercise price of $0.01 per share    
Trading Symbol CORZZ    
Security Exchange Name NASDAQ